antineoplaston a10 has been researched along with glutamine in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (36.84) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hara, H; Hirohata, M; Maruiwa, H; Shigemori, M; Sugita, Y; Tsuda, H | 1 |
| Burzynski, SR | 2 |
| Eriguchi, N; Hara, H; Kumabe, T; Nishida, H; Sugita, Y; Tsuda, H; Yoshida, H | 1 |
| Hara, H; Iemura, A; Sata, M; Tsuda, H; Uchida, M; Yamana, K | 1 |
| D'Avignon, DA; Revelle, LK; Wilson, JA | 1 |
| Ames, MM; Buckner, JC; Cascino, TL; Figg, WD; Lim, S; Malkin, MG; Reed, E; Reid, JM; Tong, WP | 1 |
| Axler, ML; Bestak, M; Burzynski, SR; Janicki, TJ; Jurida, GF; Khan, MI; Lewy, RI; Paszkowiak, JK; Szymkowski, BG; Weaver, RA | 1 |
| Matono, K; Ogata, Y; Shirouzu, K | 1 |
| Hammer, MR; Jonas, WB | 1 |
| Burzynski, SR; Janicki, T; Jurida, G; Khan, M; Larisma, CB; Lewy, RI; Paszkowiak, J; Szymkowski, B; Weaver, R | 1 |
| Bestak, M; Burzynski, SR; Janicki, TJ; Jurida, GF; Khan, MI; Lewy, RI; Szymkowski, BG; Weaver, RA | 1 |
| Burzynski, SR; Dolgopolov, V; Janicki, T; Jurida, G; Khan, M; Szymkowski, B; Weaver, RA | 1 |
| Burzynski, B; Burzynski, SR; Janicki, TJ; Weaver, RA | 1 |
| Burzynski, GS; Burzynski, SR; Janicki, TJ; Marszalek, A | 2 |
| Clerici, CA; Massimino, M | 1 |
| Di Rocco, C | 1 |
| Akagi, Y; Matono, K; Ogata, Y; Shirouzu, K; Tsuda, H; Uchida, S; Ushijima, M | 1 |
1 review(s) available for antineoplaston a10 and glutamine
| Article | Year |
|---|---|
Potential of antineoplastons in diseases of old age.
Topics: Aged; Aging; Animals; Antineoplastic Agents; Benzeneacetamides; Drug Combinations; Glutamine; Growth Inhibitors; Humans; Neoplasms; Peptides; Phenylacetates; Piperidones | 1995 |
10 trial(s) available for antineoplaston a10 and glutamine
| Article | Year |
|---|---|
Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetamides; Child; Drug Combinations; Female; Glutamine; Humans; Male; Middle Aged; Neoplasms; Phenylacetates; Piperidones | 1995 |
Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma.
Topics: Adult; Antineoplastic Agents; Astrocytoma; Benzeneacetamides; Brain Neoplasms; Confusion; Disorders of Excessive Somnolence; Drug Administration Schedule; Drug Combinations; Female; Glioblastoma; Glutamine; Humans; Injections, Intravenous; Male; Middle Aged; Patient Selection; Phenylacetates; Piperidones; Seizures; Severity of Illness Index; Treatment Outcome | 1999 |
Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetamides; Brain Stem Neoplasms; Cerebral Angiography; Child; Drug Combinations; Glioma; Glutamine; Humans; Karnofsky Performance Status; Phenylacetates; Piperidones; Risk Assessment; Time Factors | 2003 |
Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report.
Topics: Adolescent; Antineoplastic Agents; Astrocytoma; Benzeneacetamides; Brain Neoplasms; Child; Child, Preschool; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Glioma; Glutamine; Humans; Infant; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Phenylacetates; Piperidones; Survival Analysis; Treatment Outcome | 2004 |
Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1.
Topics: Antineoplastic Agents; Benzeneacetamides; Brain Neoplasms; Child, Preschool; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Glutamine; Humans; Infant; Male; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive; Phenylacetates; Piperidones; Survival Analysis; Treatment Outcome | 2005 |
Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.
Topics: Adolescent; Adult; Benzeneacetamides; Brain Stem Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Glioma; Glutamine; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Phenylacetates; Piperidones; Risk Assessment; Survival Analysis; Treatment Outcome | 2006 |
The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetamides; Brain Stem Neoplasms; Child; Child, Preschool; Disease Progression; Drug Combinations; Female; Glioma; Glutamine; Humans; Infusions, Intravenous; Male; Neoplasm Recurrence, Local; Phenylacetates; Piperidones; Pons; Survival Rate | 2014 |
Commentary: The response and survival of children with recurrent diffuse intrisic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma, by Burzynski G, et al.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetamides; Biomedical Research; Brain Stem Neoplasms; Child; Child, Preschool; Disease Progression; Drug Combinations; Female; Glioma; Glutamine; Humans; Infusions, Intravenous; Male; Neoplasm Recurrence, Local; Phenylacetates; Piperidones; Pons; Prognosis; Survival Rate; Treatment Outcome | 2014 |
Main editor's comment to the paper: the response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Stanislaw R. Burzynski, Tomasz J. Janicki
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetamides; Brain Stem Neoplasms; Child; Child, Preschool; Disease Progression; Drug Combinations; Female; Glioma; Glutamine; Humans; Infusions, Intravenous; Male; Neoplasm Recurrence, Local; Phenylacetates; Piperidones; Pons; Survival Rate; Treatment Outcome | 2014 |
Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or without antineoplastons as an adjuvant therapy after hepatectomy for liver metastases from colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetamides; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Glutamine; Hepatectomy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Phenylacetates; Piperidones; Survival Analysis; Treatment Outcome | 2015 |
8 other study(ies) available for antineoplaston a10 and glutamine
| Article | Year |
|---|---|
The effect of Antineoplaston, a new antitumor agent on malignant brain tumors.
Topics: Adult; Antineoplastic Agents; Astrocytoma; Benzeneacetamides; Brain Neoplasms; Child; Drug Combinations; Female; Glioblastoma; Glioma; Glutamine; Humans; Male; Medulloblastoma; Middle Aged; Phenylacetates; Piperidones | 1995 |
Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzeneacetamides; Carcinoma, Hepatocellular; Drug Combinations; Glutamine; Humans; Liver Neoplasms; Phenylacetates; Piperidones; Tumor Cells, Cultured | 1996 |
3-[(Phenylacetyl)amino]-2,6-piperidinedione hydrolysis studies with improved synthesis and characterization of hydrolysates.
Topics: Antineoplastic Agents; Benzeneacetamides; Chromatography, High Pressure Liquid; Glutamic Acid; Glutamine; Hydrolysis; Magnetic Resonance Spectroscopy; Mass Spectrometry; Piperidones; Reference Standards | 1996 |
Efficacy of antineoplastons A10 and AS2-1.
Topics: Antineoplastic Agents; Benzeneacetamides; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Glioma; Glutamine; Humans; National Institutes of Health (U.S.); Phenylacetates; Piperidones; Treatment Failure; United States | 1999 |
[Anti-proliferative effects of biochemical defense modifier antineoplaston in colorectal carcinoma].
Topics: Animals; Apoptosis; Benzeneacetamides; Cell Cycle; Cell Cycle Proteins; Colorectal Neoplasms; Depression, Chemical; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Glutamine; Humans; Lung Neoplasms; Mice; Mice, Nude; Phenylacetates; Piperidones; Tumor Cells, Cultured | 2003 |
Managing social conflict in complementary and alternative medicine research: the case of antineoplastons.
Topics: Benzeneacetamides; Brain Neoplasms; Clinical Trials, Phase II as Topic; Communication; Complementary Therapies; Conflict of Interest; Documentation; Drug Combinations; Glutamine; Humans; Interprofessional Relations; Phenylacetates; Physician's Role; Piperidones; Power, Psychological; Problem Solving; Social Conditions; Trust | 2004 |
Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme.
Topics: Adult; Benzeneacetamides; Brain Stem Neoplasms; Disease-Free Survival; Drug Combinations; Glioblastoma; Glutamine; Health Status; Humans; Male; Neoplasm Recurrence, Local; Phenylacetates; Piperidones; Survival Analysis; Time Factors; Treatment Outcome | 2004 |
Complete response and long-term survival (>20 years) of a child with tectal glioma: a case report.
Topics: Adolescent; Benzeneacetamides; Brain Neoplasms; Drug Combinations; Follow-Up Studies; Glioma; Glutamine; Humans; Male; Neoplasm Recurrence, Local; Phenylacetates; Piperidones; Treatment Outcome | 2015 |